title: A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
abstract: We present a fatal drug poisoning case involving venlafaxine (VEN). The deceased took his medication regularly (including 150 mg VEN twice daily), and nothing in the case or autopsy findings pointed towards suicide. The toxicological assessment concluded that the cause of death was most likely due to a poisoning with a combination of VEN, oxycodone and ethanol, and the manner of death was considered to be an accident. The blood concentration of VEN was high (4.5mg/kg), and the ratio of the VEN metabolite O-desmethylvenlafaxine (ODV) to VEN was exceptionally low (0.006). Mechanistic pharmacokinetic simulations suggested that the low metabolite ratio was the result of combined poor metabolizer (PM) status of cytochrome P450 (CYP) 2C19 and CYP2D6. This hypothesis was confirmed by genetic analysis. Simulations revealed that it was likely that the combined missing CYP2D6 and CYP2C19 activity would cause higher concentrations of VEN, but the simulations also suggested that there could be additional reasons to explain the high VEN concentration found in this case. Thus, it seems likely that the potentially toxic VEN concentration was caused by reduced metabolic capacity. The simulations combined with genotyping were considered very useful in this fatal drug poisoning case.
authors: Aarhus University, Department of Forensic Medicine, Section for Forensic Pathology and Clinical Forensic Medicine & Section for Toxicology and Drug Analysis, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark. jjor@forensic.au.dk
authors: J
authors: J
authors: Jornil
authors: T S
authors: TS
authors: Nielsen
authors: I
authors: I
authors: Rosendal
authors: J
authors: J
authors: Ahlner
authors: A L
authors: AL
authors: Zackrisson
authors: L W T
authors: LW
authors: Boel
authors: B
authors: B
authors: Brock
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000097:blood / Q000506:poisoning; D018687:Antidepressive Agents, Second-Generation / Q000097:blood / Q000493:pharmacokinetics / Q000506:poisoning*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D002492:Central Nervous System Depressants / Q000097:blood / Q000652:urine; D003511:Cyclohexanols / Q000097:blood / Q000493:pharmacokinetics / Q000506:poisoning*; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D000069468:Desvenlafaxine Succinate; D000431:Ethanol / Q000097:blood / Q000652:urine; D053593:Forensic Toxicology; D017353:Gene Deletion; D020440:Gene Duplication; D005838:Genotype; D006801:Humans; D008297:Male; D010098:Oxycodone / Q000097:blood / Q000506:poisoning; D020641:Polymorphism, Single Nucleotide; D000069470:Venlafaxine Hydrochloride
chemical_list: D000701:Analgesics, Opioid; D018687:Antidepressive Agents, Second-Generation; D002492:Central Nervous System Depressants; D003511:Cyclohexanols; D000431:Ethanol; D000069470:Venlafaxine Hydrochloride; D010098:Oxycodone; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D000069468:Desvenlafaxine Succinate